Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ruxolitinib in Myelofibrosis and Polycythemia Vera

Progression of primary myelofibrosis to polycythemia vera

RATIONALE This case report describes the progression of primary myelofibrosis (PMF) to polycythemia vera (PV), and discuss its potential mechanisms. PATIENT CONCERNS The patient was admitted because of abdominal discomfort and enlarged spleen for 19 months. DIAGNOSIS A case of PMF progressed to PV was retrospectively analyzed. There were 19 months between the diagnosis of PMF and PV. The JA...

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera

Dermatomyositis (DM) is a unique inflammatory myopathy with clinical findings of proximal muscle weakness, characteristic rash, and elevated muscle enzymes. The association of DM and malignancy, most commonly adenocarcinoma, is well known. There have been few case reports of primary myelofibrosis associated with DM. We present the case of a 69-year-old male with a history of polycythemia vera (...

Doctor's Brochure 2004 Myeloproliferative Disorders: MPDs Essential Thrombocythemia: ET Polycythemia Vera: PV Chronic Idiopathic Myelofibrosis: IMF

This Doctor's MPD Brochure provides basic information for MPD patients and their doctors to better find their way in order to improve proper diagnosis and manage

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We examined the effect of these mutations on long-term disease outcome. One thousand five hundred eighty-one patients from the Mayo Clinic (n = 826) and Ita...